Should you buy Moderna stock in 2020?
To be clear, Moderna was still a speculative purchase in April of 2020. At that point, wise investors were hedging their bets by making small positions in a handful of different vaccine developers. Nonetheless, even conservative investors had a significant opportunity to get a huge return from this stock.
What is the all-time high Moderna stock price?
The all-time high Moderna stock closing price was 484.47 on August 09, 2021. The Moderna 52-week high stock price is 497.49, which is 93.5% above the current share price.
Is Moderna's $29 billion market value too high?
Moderna's market value swelled to $29 billion -- even though the company has no marketed products. After spiking to as high as $87 on Monday, Moderna's stock price has since retreated below $70 as medical experts have debated the importance of the early findings.
Is Moderna the hottest Biotech stock on the market?
Moderna ( MRNA -5.16%) is one of the hottest biotechs on the market thanks to its rapid development of a functional coronavirus vaccine. Fueled by astronomically high predictions of its vaccine revenue, the stock continues to ascend higher and higher.
See more
When will Moderna be available to the public?
How much did Lorence Kim sell Moderna?
If future studies go well, Moderna has said its vaccine could be available to the public as early as January. Charles Elson, a corporate governance expert at the University of Delaware, said the Moderna stock sales underscore why he has always believed executives should not sell stock while they are at the company.
Did the US buy Moderna?
Lorence Kim, Moderna's chief financial officer, exercised 241,000 options for $3 million on Monday, filings show. He then immediately sold them for $19.8 million, creating a profit of $16.8 million. In quest for vaccine, US makes 'big bet' on company with unproven technology.
Does Moderna work in Japan?
The U.S. government has bought another 200 million doses of Moderna's COVID-19 vaccine, the drugmaker said on Wednesday, including an option to buy experimental shots that may be in development. Moderna is currently conducting clinical trials testing a third booster shot of its authorized vaccine as well as an experimental one to protect against coronavirus variants. The U.S. government last August signed a $1.53 billion deal with Moderna for 100 million vaccine doses, with an option to buy 400 million more.
Is Pfizer crushing Moderna?
Takeda Pharmaceutical Co said on Tuesday it agreed to supply an additional 50 million doses of Moderna In c's COVID -19 vaccine to Japan. Takeda CEO Christophe Weber had said in May that talks were underway to potentially double the Moderna shipments to help Japan speed up its inoculation efforts.
Is Moderna stock down?
3 Areas Where Pfizer Is Crushing Moderna. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have been marching in lockstep for nearly a year. Pfizer won Emergency Use Authorization for its vaccine only about a week ahead of Moderna. It's fair to say both of these companies today are leading the coronavirus vaccine market.
What happened
Shares of Moderna Inc. were down 1.2% in premarket trading on Wednesday after the company said the U.S. has agreed to buy an additional 200 million doses of its COVID-19 vaccine. This agreement includes the option to purchase other COVID-19 vaccine candidates that Moderna is developing. This could include booster shots, Moderna executives said in a news release. In total, the U.S. has ordered 500 million doses of the company's mRNA vaccine. Moderna's stock has soared 92.9% this year, while the S
NASDAQ: MRNA
Shares of clinical-stage biotech Moderna ( MRNA -3.14% ) rose 15.5% in March, according to data from S&P Global Market Intelligence .
So what
There's no COVID-19 vaccine yet, but many companies are working on developing one. Image source: Getty Images.
Now what
We can attribute Moderna stock's robust performance last month to investor enthusiasm about the company's prospects for developing a vaccine to immunize people against COVID-19, the disease caused by the novel coronavirus.
Premium Investing Services
Moderna aims to begin phase 2 trials in the spring or early summer. If all goes as planned, it expects to have a vaccine available for public distribution in 12 to 18 months. That's super speedy in the world of vaccine development, yet it seems like too long a time given how fast the virus is spreading.
NASDAQ: MRNA
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
You'd be sitting pretty, to say the least
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Was the stock a buy before 2020?
Moderna ( MRNA -4.74% ) is one of the hottest biotechs on the market thanks to its rapid development of a functional coronavirus vaccine. Fueled by astronomically high predictions of its vaccine revenue, the stock continues to ascend higher and higher.
NASDAQ: MRNA
With an abundance of fanfare, Moderna went public in late 2018, and it was the largest biotech initial public offering (IPO) in history at the time. The company already had a reputation for a frothy valuation thanks to significant fundraising with the help of its venture capital partners.
Investing extremely early wasn't necessary to win big
Still, there were a few reasons to find the company appealing at the time, starting with its then-unproven mRNA technology platform.
Sometimes it's better not to worry about being too late
Let's assume that as a savvy biotech investor with a diversified portfolio, you found Moderna's pipeline to be especially attractive and made a speculative investment of $2,000 on Sep. 9, 2019, when Moderna's stock was at $16.71. Now, it's around $431, and it could rise even further over the next few months.
Premium Investing Services
To be clear, Moderna was still a speculative purchase in April of 2020. At that point, wise investors were hedging their bets by making small positions in a handful of different vaccine developers. Nonetheless, even conservative investors had a significant opportunity to get a huge return from this stock.
Your gains would be impressive. And they may not be over
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Gaining steam
Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories.
Is now too late to invest?
Moderna traded lower than $20 a share in January and February. But the stock began to gain steam in early March -- climbing to more than $29 -- as it became clear Moderna would be a significant player in the vaccine race. Then came the crash that pulled the stock down to a March low of $21.30.
The finish line
So, now, should you stay invested? And if you haven't yet purchased Moderna shares, is it too late? First, let me preface this by saying only aggressive investors with a tolerance for risk should invest in/hold onto shares of Moderna at this point.
